These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 26841903)
1. RRx-001, A novel dinitroazetidine radiosensitizer. Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S Invest New Drugs; 2016 Jun; 34(3):371-7. PubMed ID: 26841903 [TBL] [Abstract][Full Text] [Related]
2. Rockets, radiosensitizers, and RRx-001: an origin story part I. Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167 [TBL] [Abstract][Full Text] [Related]
3. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Oronsky B; Scicinski J; Cabrales P; Minchinton A Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220 [TBL] [Abstract][Full Text] [Related]
4. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533 [TBL] [Abstract][Full Text] [Related]
5. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511 [TBL] [Abstract][Full Text] [Related]
6. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332 [TBL] [Abstract][Full Text] [Related]
7. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Cabrales P; Scicinski J; Reid T; Kuypers F; Larkin S; Fens M; Oronsky A; Oronsky B Med Oncol; 2016 Jul; 33(7):63. PubMed ID: 27229330 [TBL] [Abstract][Full Text] [Related]
8. RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia. Oronsky B; Cabrales P; Caroen S; Guo X; Scribner C; Oronsky A; Reid TR Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):355-357. PubMed ID: 33432831 [No Abstract] [Full Text] [Related]
9. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731 [TBL] [Abstract][Full Text] [Related]
10. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Ning S; Bednarski M; Oronsky B; Scicinski J; Saul G; Knox SJ Cancer Res; 2012 May; 72(10):2600-8. PubMed ID: 22589277 [TBL] [Abstract][Full Text] [Related]
11. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403 [TBL] [Abstract][Full Text] [Related]
12. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360 [TBL] [Abstract][Full Text] [Related]
13. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336 [TBL] [Abstract][Full Text] [Related]
14. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature. Jani VP; Asaro R; Oronsky B; Cabrales P Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824 [TBL] [Abstract][Full Text] [Related]
15. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482 [TBL] [Abstract][Full Text] [Related]
16. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. Oronsky B; Scribner C; Aggarwal R; Cabrales P J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159 [TBL] [Abstract][Full Text] [Related]
17. RRx-001 protects against cisplatin-induced toxicities. Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195 [TBL] [Abstract][Full Text] [Related]
18. Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. Oronsky B; Reid T; Cabrales P J Drug Target; 2021 Nov; 29(9):998-1003. PubMed ID: 34016002 [TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Scicinski J; Oronsky B; Taylor M; Luo G; Musick T; Marini J; Adams CM; Fitch WL Drug Metab Dispos; 2012 Sep; 40(9):1810-6. PubMed ID: 22699395 [TBL] [Abstract][Full Text] [Related]
20. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001. Cirrik S; Ugurel E; Aksu AC; Oronsky B; Cabrales P; Yalcin O Biorheology; 2019; 56(4):221-235. PubMed ID: 31640080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]